코비시스타트 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "코비시스타트" in Korean language version.

refsWebsite

Global rank Korean rank

6doi.org

2^nd place

3^rd place

6nih.gov

4^th place

2archive.org

6^th place

18^th place

2web.archive.org

1^st place

1semanticscholar.org

11^th place

310^th place

1hivandhepatitis.com

low place

1drugs.com

399^th place

141^st place

1wipo.int

1,462^nd place

2,838^th place

1harvard.edu

18^th place

27^th place

archive.org

Mathias AA, German P, Murray BP, Wei L, Jain A, West S, 외. (March 2010). “Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity”. 《Clinical Pharmacology and Therapeutics》 87 (3): 322–9. doi:10.1038/clpt.2009.228. PMID 20043009. S2CID 29197109.
Lepist EI, Phan TK, Roy A, Tong L, Maclennan K, Murray B, Ray AS (October 2012). “Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro”. 《Antimicrobial Agents and Chemotherapy》 56 (10): 5409–13. doi:10.1128/AAC.01089-12. PMC 3457391. PMID 22850510.

doi.org

dx.doi.org

Mathias AA, German P, Murray BP, Wei L, Jain A, West S, 외. (March 2010). “Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity”. 《Clinical Pharmacology and Therapeutics》 87 (3): 322–9. doi:10.1038/clpt.2009.228. PMID 20043009. S2CID 29197109.
Lepist EI, Phan TK, Roy A, Tong L, Maclennan K, Murray B, Ray AS (October 2012). “Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro”. 《Antimicrobial Agents and Chemotherapy》 56 (10): 5409–13. doi:10.1128/AAC.01089-12. PMC 3457391. PMID 22850510.
Xu L, Liu H, Murray BP, Callebaut C, Lee MS, Hong A, 외. (August 2010). “Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer”. 《ACS Medicinal Chemistry Letters》 1 (5): 209–13. doi:10.1021/ml1000257. PMC 4007915. PMID 24900196.
Xu L, Liu H, Hong A, Vivian R, Murray BP, Callebaut C, 외. (February 2014). “Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350)”. 《Bioorganic & Medicinal Chemistry Letters》 24 (3): 995–9. doi:10.1016/j.bmcl.2013.12.057. PMID 24412072.
Sevrioukova IF, Poulos TL (July 2013). “Dissecting cytochrome P450 3A4-ligand interactions using ritonavir analogues”. 《Biochemistry》 52 (26): 4474–81. doi:10.1021/bi4005396. PMID 23746300.
Sevrioukova IF, Poulos TL (October 2010). “Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir”. 《Proceedings of the National Academy of Sciences of the United States of America》 107 (43): 18422–7. Bibcode:2010PNAS..10718422S. doi:10.1073/pnas.1010693107. PMC 2973003. PMID 20937904.

drugs.com

“Symtuza (cobicistat, darunavir, emtricitabine and tenofovir alafenamide) FDA Approval History”. 《Drugs.com》 (영어). 2019년 10월 30일에 확인함.

harvard.edu

adsabs.harvard.edu

Sevrioukova IF, Poulos TL (October 2010). “Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir”. 《Proceedings of the National Academy of Sciences of the United States of America》 107 (43): 18422–7. Bibcode:2010PNAS..10718422S. doi:10.1073/pnas.1010693107. PMC 2973003. PMID 20937904.

hivandhepatitis.com

Highleyman, L. Elvitegravir "Quad" Single-tablet Regimen Shows Continued HIV Suppression at 48 Weeks Archived 2016년 3월 3일 - 웨이백 머신. HIV and Hepatitis.com

nih.gov

ncbi.nlm.nih.gov

Mathias AA, German P, Murray BP, Wei L, Jain A, West S, 외. (March 2010). “Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity”. 《Clinical Pharmacology and Therapeutics》 87 (3): 322–9. doi:10.1038/clpt.2009.228. PMID 20043009. S2CID 29197109.
Lepist EI, Phan TK, Roy A, Tong L, Maclennan K, Murray B, Ray AS (October 2012). “Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro”. 《Antimicrobial Agents and Chemotherapy》 56 (10): 5409–13. doi:10.1128/AAC.01089-12. PMC 3457391. PMID 22850510.
Xu L, Liu H, Murray BP, Callebaut C, Lee MS, Hong A, 외. (August 2010). “Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer”. 《ACS Medicinal Chemistry Letters》 1 (5): 209–13. doi:10.1021/ml1000257. PMC 4007915. PMID 24900196.
Xu L, Liu H, Hong A, Vivian R, Murray BP, Callebaut C, 외. (February 2014). “Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350)”. 《Bioorganic & Medicinal Chemistry Letters》 24 (3): 995–9. doi:10.1016/j.bmcl.2013.12.057. PMID 24412072.
Sevrioukova IF, Poulos TL (July 2013). “Dissecting cytochrome P450 3A4-ligand interactions using ritonavir analogues”. 《Biochemistry》 52 (26): 4474–81. doi:10.1021/bi4005396. PMID 23746300.
Sevrioukova IF, Poulos TL (October 2010). “Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir”. 《Proceedings of the National Academy of Sciences of the United States of America》 107 (43): 18422–7. Bibcode:2010PNAS..10718422S. doi:10.1073/pnas.1010693107. PMC 2973003. PMID 20937904.

semanticscholar.org

api.semanticscholar.org

Mathias AA, German P, Murray BP, Wei L, Jain A, West S, 외. (March 2010). “Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity”. 《Clinical Pharmacology and Therapeutics》 87 (3): 322–9. doi:10.1038/clpt.2009.228. PMID 20043009. S2CID 29197109.

web.archive.org

Highleyman, L. Elvitegravir "Quad" Single-tablet Regimen Shows Continued HIV Suppression at 48 Weeks Archived 2016년 3월 3일 - 웨이백 머신. HIV and Hepatitis.com
“WO 2016128885” (PDF). 2019년 8월 14일에 원본 문서 (PDF)에서 보존된 문서. 2021년 6월 23일에 확인함.

wipo.int

patentscope.wipo.int

“WO 2016128885” (PDF). 2019년 8월 14일에 원본 문서 (PDF)에서 보존된 문서. 2021년 6월 23일에 확인함.